Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedr...

Full description

Bibliographic Details
Main Authors: Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD
Format: Article
Language:English
Published: Dove Medical Press 2021-02-01
Series:Journal of Blood Medicine
Subjects:
annualized bleeding rate
antibodies
bispecific
comparative effectiveness research
efmoroctocog alfa
factor viii deficiency
treatment outcome
Online Access:https://www.dovepress.com/efficacy-of-rfviiifc-versus-emicizumab-for-the-treatment-of-patients-w-peer-reviewed-article-JBM

Internet

https://www.dovepress.com/efficacy-of-rfviiifc-versus-emicizumab-for-the-treatment-of-patients-w-peer-reviewed-article-JBM

Similar Items